期刊文献+

孕激素受体膜组分1(PGRMC1)对预测乳腺癌预后作用的研究 被引量:6

Study of prognostic impact of progesterone receptor membrane component 1( PGRMC1) in breast cancer patients
下载PDF
导出
摘要 目的探讨孕激素受体膜组分1(progesterone receptor membrane component 1,PGRMC1)在乳腺癌患者预后方面的作用及临床意义,为评估患者预后提供更多的预测依据。方法试验纳入2008年1月1日至2014年12月31日间初诊诊断为乳腺癌的患者50例,记录患者年龄、肿瘤直径、病理分级、淋巴结转移等预后相关因素,追踪随访患者预后情况,免疫组织化学方法检测乳腺癌组织标本雌激素受体α(estrogen receptorα,ERα)、孕激素受体(progesterone receptor,PR)、Ki67、PGRMC1表达情况,并分析与患者预后之间的相关性。结果纳入试验的50名女性乳腺癌患者,乳腺癌组织ERa阳性表达率为48.0%,共24例;PR阳性表达率为42.0%,共21例;Ki67阳性表达率为4%,共2例;PGRMC1阳性表达率为70.0%,共35例。PGMRC1的表达与年龄、肿瘤病理分级之间无明显相关性,与肿瘤直径、淋巴结转移间有明显相关性(OR=1.60,95%CI:1.11-2.29;OR=1.12,95%CI:1.02-1.23),PGRMC1表达阳性程度越高,患者复发可能性越大(P=0.011),远期生存情况越差(P=0.028)。结论PGRMC1与常见预后因子肿瘤直径、淋巴结转移间存在关联,与患者疾病复发、远期生存情况存在关联,其很有可能成为乳腺癌患者预后的独立预测因子。 Objective The aim of this study was to investigate the potential clinical prognosis significance of progesterone receptor membrane component 1 (PGRMC1) for breast cancer patients. Methods Fifty cases of breast cancer patients were derived from the Beijing Obstetrics and Gynecology hospital, Capital Medical University from Jan. 2008 to Dec 2014. Clinical and pathological data in details, such as date of primary diagnosis date, age, histologic grade, tumor size, lymph node metastasis, and patient follow-up information were collected and retrospectively analyzed. Immunohistochemical staining were carried out manually to evaluated the expression of estrogen receptor α(ERα) ,progesterone receptor(PR) ,Ki67 and PGRMC1 in breast cancer samples. Results For all the 50 tissues, the hormonal receptor status was 48.0% ERα positive ( n = 24 ), 42.0% PR positive ( n = 21 ), 4% Ki67 positive ( n = 2). Of the samples, 70.0% (n= 35 ) were PGRMC1 positive. The result showed one statistically significant correlation, between PGRMC1 and tumor size, lymph node metastas (OR = 1.60, 95% CI: 1. 11-2.29; OR = 1. 12, 95% CI: 1.02-1.23 ). The association between conventional clinicopathological features and prognosis in breast cancer patients were evaluated. PGRMC1 expression would be used as predictors of recurrence (P = 0.011 ) and poor overall survival (P = 0. 028 ) in breast cancer patients in Cox' s proportional hazard model. Conclusion The high PGRMC1 level was associated with poor disease free survival rate and overall survival rate. PGRMC1 might be a independent prognostic factor breast cancer in the future.
出处 《首都医科大学学报》 CAS 北大核心 2015年第4期548-552,共5页 Journal of Capital Medical University
基金 国家自然科学基金项目(81172518) 北京市科技新星交叉合作项目(Z14111000180000) 北京市卫生系统高层次卫生技术人才培养计划项目(2014-2-016) 首都医科大学附属北京妇产医院学科带头人项目(2013-1)~~
关键词 乳腺癌 孕激素受体膜组分1 雌激素受体 预后因子 breast cancer progesterone receptor membrane component 1 (PGRMC1) estrogen receptor prognosis factor
  • 相关文献

参考文献7

二级参考文献136

  • 1尹子毅,刘晖,李洪利,王丕琳,张铁,宋茂民.乳腺癌组织p53和Ki-67表达及其与新辅助化疗关系的研究[J].中华肿瘤防治杂志,2008,15(9):676-678. 被引量:10
  • 2Markhoul I,Kiwan E. Neoadiuvant systemic treatment of breast cancer[J]. J Surg Oncol, 2011,103 (4): 348-357.
  • 3魏少琳.三阴性乳腺癌的新辅助化疗的疗效及预后对比分析[J].中国煤炭医学杂志,2010,13(11):1621-1622.
  • 4Nishimura R,Osako T,Okumura Y, et al. Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis[J]. Breast Cancer,2010,17(4) :269-275.
  • 5Gralow JR,Burstein HJ,Wood W, et al. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease[J]. J Clin Oncol, 2008,26(5) : 814-819.
  • 6Fisher B,Bryant J,Wolmark N,et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer[J]. J Clin Oncol, 1998,16(8) :2672-2685.
  • 7Bear HD,Anderson S, Brown A,et al. The effect on tumor response of adding sequential preoperative docetaxel to preoprative doxorubicin and cyclophosphamide; preliminary results from national surgical adjuvant breast and bowel project protocol B-27 [J]. J Clin Oncol,2003,21(22) ,4165-4174.
  • 8Taucher S, Rudas M, Gnant M, et al. Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy[J]. Endocr Relat Cancer, 2003,10(1) : 91-98.
  • 9Untch M,Rezai M,Loibl S,et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast eancer: Results from the Gepar Ouattro study[J]. J Clin Oncol,2010,28(12):2024-2031.
  • 10Keskin S, Muslumanoglu M,Saip P, et al. Clinical and pathological features of breast cancer associated with the pathological complete response to anthracycline-based neoadiuvant chemotherapy[J]. Oncology,2011,81(1) :30-38.

共引文献270

同被引文献52

引证文献6

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部